Mankind Pharma Ltd

ESG Rating Update

• CRISIL ESG Ratings assigns Mankind Pharma ESG score of 64 in Strong category.
• Core ESG Rating improved to 71 from 60.
• Company states it did not engage CRISIL; report prepared independently using FY2026 disclosures and public data.
• Disclosure available on the Mankind Pharma website.
• No direct financial impact or metrics disclosed.

Deal overview

• Mankind Pharma signed an exclusive in-licensing and marketing agreement for Insulin Degludec and Degludec + Aspart in India.
• The deal strengthens the company's diabetes portfolio and injectables footprint in India.
• The licensor is Chongqing Chenan Biopharmaceutical Co., Ltd., China.
• The release highlights expansion of access to advanced therapies in India.

Resolution details

• Purpose: obtain Special Resolution approval to appoint Anish Vanraj Bafna as Non-Executive Independent Director.
• Type: Special Resolution.
• Appointment: Additional Director, Non-Executive Independent, for five years from August 10, 2026.
• Independence: meets independence criteria under Section 149(6) and Listing Regulations; not debarred.
• Experience: 30+ years in healthcare; former Healthium CEO/MD; prior Baxter leadership.
• Compensation: sitting fees, expenses, and profit-linked commission as board decides.
• Notes: not liable to retirement by rotation; appointment subject to member approval.
• Voting window: e-voting Aug 19, 2026 to Sep 17, 2026; results by Sep 21, 2026.
• Cut-off: Aug 14, 2026; only members as on cut-off may vote.
• Result status: results not yet declared; to be announced after Scrutinizer report.

NCD security realignment

• Security cover realignment completed for NCDs, pledged BSVL shares released on August 17, 2026.
• Revised security equals 1.26x outstanding NCDs as of date.
• 28,280 BSVL equity shares (38.68% of BSVL paid-up capital) released from pledge.
• Revised security over tangible and intangible assets created for Catalyst Trusteeship Limited.
• Approvals from NCD holders and BSE obtained on July 13 and July 21, 2026.
• No BSVL shares remain pledged against NCDs.

Netherlands subsidiary

• Target: Mankind Pharma (Netherlands) B.V., Netherlands-based pharmaceuticals subsidiary.
• Ownership: 100% owned by Mankind Pharma Ltd.
• Incorporated on August 13, 2026 in the Netherlands.

Appointments/Resignations

• Appointment of Mr. Anish Vanraj Bafna as Additional Non-Executive Independent Director, effective Aug 10, 2026.
• Term of 5 consecutive years, subject to member approval.
• Postal Ballot Notice to seek member approval for the appointment for 5-year term.
• Mr. Bafna has 30+ years in healthcare; former CEO/MD Healthium Medtech.
• Not debarred from director office per SEBI circulars.

Meeting Details

• Dates: August 13, 2026 and August 17, 2026; Location: Mumbai.
• Meeting type: One-on-One / Group Meeting; Mode: not specified.
• Event names: Emkay Confluence; Equirus Annual India Conference ’26; Motilal Oswal Global Investor Conference ’26.
• Key participants: Company management/officials.
• Purpose: Intimation of participation; discussions on general business outlook.
• Notes: UPSI not disclosed; schedule subject to change.

AGM details

• AGM held August 4, 2026, 3:30 PM–4:56 PM IST via VC/OAVM.
• Record date for eligibility: 29 July 2026.

Key resolutions

• Adopt standalone and consolidated financial statements for year ended March 31, 2026.
• Re-appointment of Rajeev Juneja as Director (retires by rotation).
• Re-appointment of Satish Kumar Sharma as Whole-time Director.
• Ratification of remuneration of cost auditors for FY2026-27.

Voting results

• Item 1: 99.29% in favour, 0.71% against.
• Item 2: 98.89% in favour, 1.11% against.
• Item 3: 98.89% in favour, 1.11% against.
• Item 4: 100% in favour, 0% against.

Dividend

• No dividend proposed or declared.

Directors changes

• Rajeev Juneja reappointed as Director (by rotation).
• Satish Kumar Sharma continues as Whole-time Director.

Auditors

• Cost auditors' remuneration for FY2026-27 ratified.

Related party transactions

• No material related party transactions disclosed.

Other material approvals

• No additional material approvals reported.